CLAIMS

1. A compound represented by general formula (1):



(I)

wherein X^1 is (1) a nitrogen atom or (2) C-R^6; X^2 is (1) a nitrogen atom or (2) C-R^7; R^{11} is (1) OR^1 or (2) NH_2; R^1 is (1) a hydrogen atom or (2) a C1-4 alkyl group; R^2 and R^3 are each independently (1) a hydrogen atom, or (2) a C1-4 alkyl group which may be substituted with halogen, where both R^2 and R^3 are not simultaneously a hydrogen atom; R^4, R^5, R^6, and R^7 are each independently (1) a hydrogen atom, (2) halogen, (3) a C1-4 alkyl group which may be substituted with halogen, or (4) a C1-4 alkoxy group which may be substituted with halogen, where both R^4 and R^5 are not simultaneously a hydrogen atom; Y is (1) -NH-, (2) -O-, or (3) a bond; R^8 is (1) a hydrogen atom or (2) a C1-4 alkyl group which may be substituted with halogen or a hydroxy group; R^9 is (1) a ring A, (2) a C1-6 alkyl group, (3) a C2-6 alkenyl group, (4) a C2-6 alkynyl group, (5) -C1-4 alkylene group-ring A, (6) -C2-4 alkenylene group-ring A, (7) -C2-4 alkynylene group-ring A, (8) -ring B-ring C, (9) -ring B-C1-4 alkylene group-ring C, (10) -ring B-C2-4 alkenylene group-ring C, (11) -ring B-C2-4 alkynylene group-ring C, or (12) -ring B-O-ring C, where the alkyl group, alkenyl group, alkynyl group, alkylene group, alkenylene group or alkynylene group each may be substituted with halogen or a hydroxy group; the ring A is (1) C3-8 cycloalkane, (2) 3- to 8-membered

heterocycloalkane, (3) a C3-12 monocyclic or bicyclic unsaturated carbocyclic ring, or which may be partially saturated, or (4) 3- to 12-membered monocyclic or bicyclic unsaturated heterocycle including one to four heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom, or which may be partially saturated; ring B and ring C are each independently (1) C3-8 cycloalkane, (2) 3- to 8-membered heterocycloalkane, (3) a C3-7 monocyclic unsaturated carbocyclic ring, or which may be partially saturated, or (4) 3- to 7-membered monocyclic unsaturated heterocycle including one to three heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, or which may be partially saturated; where the ring A, ring B and ring C each independently may be substituted with one to five R^{10}, and when a plurality of R^{10} is present, the plurality of R^{10} may be the same as or different from each other; R^{10} is (1) halogen, (2) a hydroxy group, (3) a cyano group, (4) a C1-6 alkyl group which may be substituted with halogen or a hydroxy group, (5) a C1-6 alkoxy group which may be substituted with halogen or a hydroxy group, or (6) an amino group which may be substituted with a C1-4 alkyl group or a C2-5 acyl group, excluding N-ethyl-N'-[2-bromo-4-(hexafluoro-2-hydroxy-2-propyl)phenyl]urea, a salt thereof, a solvate thereof, or a cocrystal thereof.

2. The compound according to claim 1, wherein Y is -NH- or a bond, a salt thereof, a solvate thereof, or a cocrystal thereof.

3. The compound according to claim 1 or 2, wherein X^1 is C-R^6, and X^2 is C-R^7, a salt thereof, a solvate thereof, or a cocrystal thereof.

4. The compound according to any one of claims 1 to 3, which is represented by general formula (II):



(II)

wherein the symbols represent the same meaning as described in claim 1, a salt thereof, a solvate thereof, or a cocrystal thereof.

5. The compound according to any one of claims 1 to 4, wherein R^1 is a hydrogen atom, a salt thereof, a solvate thereof, or a cocrystal thereof.

6. The compound according to any one of claims 1 to 5, wherein one of R^2 and R^3 is a methyl group which may be substituted with halogen, and the other is a hydrogen atom or a methyl group which may be substituted with halogen, a salt thereof, a solvate thereof, or a cocrystal thereof.

7. The compound according to any one of claims 1 to 6, wherein R^6 is a hydrogen atom or halogen, and R^7 is a hydrogen atom, a salt thereof, a solvate thereof, or a cocrystal thereof.

8. The compound according to any one of claims 1 to 7, which is represented by general formula (II-1):



(II-1)

wherein R^6 is a hydrogen atom or halogen, and the other symbols represent the same meaning as described in claim 1, a salt thereof, a solvate thereof, or a cocrystal thereof.

9. The compound according to any one of claims 1 to 7, which is represented by general formula (II-2):



(II-2)

wherein R^6 is a hydrogen atom or halogen, and the other symbols represent the same meaning as described in claim 1, a salt thereof, a solvate thereof, or a cocrystal thereof.

10. The compound according to any one of claims 1 to 9, wherein R^4 and R^5 are each independently halogen or a methyl group, a salt thereof, a solvate thereof, or a cocrystal thereof.

11. The compound according to any one of claims 1 to 10, wherein R^8 is a hydrogen atom or a methyl group, a salt thereof, a solvate thereof, or a cocrystal thereof.

12. The compound according to claim 1, wherein the compound is:

(1)

1-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[5-(trifluoro methyl)-2-pyridinyl]methyl}urea,

(2)

1-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[5-(trifluoro methyl)-2-pyrimidinyl]methyl}urea,

(3)

1-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[6-(trifluoro methyl)-3-pyridinyl]methyl}urea,

(4)

1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-p ropanyl]phenyl}urea,

(5)

1-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[3-(trifluoro methyl)-1,2,4-oxadiazole-5-yl]methyl}urea,

(6)

1-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[5-(trifluoro methyl)-2-pyrimidinyl]methyl}urea,

(7)

1-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[6-(trifluoro methyl)-3-pyridinyl]methyl}urea,

(8)

1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-p ropanyl]phenyl}urea,

(9)

1-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[3-(trifluoro methyl)-1,2,4-oxadiazole-5-yl]methyl}urea,

(10)

1-{2,6-dichloro-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[3-(trifluoromethyl)-1,2,4-oxadiazole-5-yl]methyl}urea,

(11)

1-{2,6-dichloro-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[2-(trifluoromethyl)-5-pyrimidinyl]methyl}urea,

(12)

1-{2,6-dichloro-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyrimidinyl]methyl}urea,

(13)

1-{2,6-dichloro-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[2-(trifluoromethyl)-1,3-thiazole-5-yl]methyl}urea,

(14)

1-{2,6-dichloro-4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[3-(trifluoromethyl)-1,2,4-oxadiazole-5-yl]methyl}urea,

(15)

1-{2,6-dichloro-4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[2-(trifluoromethyl)-5-pyrimidinyl]methyl}urea,

(16)

1-{2,6-dichloro-4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[2-(trifluoromethyl)-1,3-thiazole-5-yl]methyl}urea,

(17)

1-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyridinyl]methyl}urea, or

(18)

1-{2,6-dichloro-4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyrimidinyl]methyl}urea,

a salt thereof, a solvate thereof, or a cocrystal thereof.

13. A pharmaceutical composition comprising a compound represented by the general formula (I), a salt thereof, a solvate thereof, or a cocrystal thereof, and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition according to claim 13, which is a preventive and/or therapeutic agent for a KCNQ2-5 channel-related disease.

15. The pharmaceutical composition according to claim 14, wherein the KCNQ2-5 channel-related disease is dysuria.

16. The pharmaceutical composition according to claim 15, wherein the dysuria is overactive urinary bladder.

17. A compound represented by the general formula (I), a salt thereof, a solvate thereof, or a cocrystal thereof, for preventing and/or treating a KCNQ2-5 channel-related disease.

18. Use of a compound represented by the general formula (I), a salt thereof, a solvate thereof, or a cocrystal thereof, for producing a preventive and/or therapeutic agent for a KCNQ2-5 channel-related disease.

19. A compound of formula 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.